Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Dr. Prakash Raman appointed independent Class II director effective April 28, 2026, serving through the 2028 annual meeting.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Prakash Raman appointed independent Class II director effective April 28, 2026, serving through the 2028 annual meeting
- Board expansion adds a Nasdaq-independent director with no reported related-party transactions or selection arrangements
- Initial equity award: option for 24,150 shares, vesting monthly over 36 months
- Partial-year equity award: option for 2,911 shares, fully vesting June 11, 2026
- Standard indemnification agreement adds customary director liability protection
Item 7.01 · Regulation FD Disclosure
- Dr. Raman appointed to Olema Pharmaceuticals’ Board
- Board refresh may add relevant expertise and influence strategic oversight
- Details on Dr. Raman’s background and appointment rationale in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Prakash Raman, Ph.D. appointed to Olema’s Board, adding over two decades of biopharma business-development and portfolio expertise
- Board addition supports palazestrant’s two Phase 3 trials and OP-3136’s Phase 1 development
- OPERA-01 pivotal data expected this fall, creating a near-term clinical catalyst for investors
- Raman’s Novartis licensing and acquisition experience may strengthen Olema’s partnering and commercialization strategy
- Appointment supports Olema’s stated transition toward a fully integrated oncology company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.